Scopus BioPharma Inc.
SCPS
$0.0003
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.59% | -1.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.30% | 45.96% | |||
| Operating Income | -9.30% | -45.96% | |||
| Income Before Tax | -9.30% | -45.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.30% | -45.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 35.90% | 118.65% | |||
| Net Income | -6.81% | -41.54% | |||
| EBIT | -9.30% | -45.96% | |||
| EBITDA | -9.30% | -45.96% | |||
| EPS Basic | 18.46% | 1.71% | |||
| Normalized Basic EPS | 19.75% | 3.64% | |||
| EPS Diluted | 18.46% | 1.71% | |||
| Normalized Diluted EPS | 19.75% | 3.64% | |||
| Average Basic Shares Outstanding | 30.86% | 43.97% | |||
| Average Diluted Shares Outstanding | 30.86% | 43.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||